| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
Gao J, Song P. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: expectation[J]. Drug Discov Ther, 2017, 11(3):168-169.
|
| [3] |
Lacroix M, Riscal R, Arena G, et al. Metabolic functions of the tumor suppressor p53: implications in normal physiology, metabolic disorders, and cancer[J]. Mol Metab, 2020(33):2-22.
|
| [4] |
Lee T, Pelletier J. The biology of DHX9 and its potential asa therapeutic target[J]. Oncotarget, 2016, 7(27):42716-42739.
|
| [5] |
Halaby MJ, Harris BRE, Miskimins WK, et al. Deregulation of internal ribosome entry site-mediated p53 translation in cancer cells with defective p53 response to DNA damage[J]. Mol Cell Biol, 2015, 35(23):4006-4017.
|
| [6] |
Fidaleo M, De Paola E, Paronetto MP. The RNA helicase A in malignant transformation[J]. Oncotarget, 2016, 7(19):28711-28723.
|
| [7] |
Cao S, Sun R, Wang W, et al. RNA helicase DHX9 may bea therapeutic target in lung cancer and inhibited by enoxacin[J]. Am J Transl Res, 2017, 9(2):674-682.
|
| [8] |
Pao GM, Janknecht R, Ruffner H, et al. CBP/p300 interact with and function as transcriptional coactivators of BRCA1[J]. Proc Natl Acad Sci U S A, 2000, 97(3):1020-1025.
|
| [9] |
Fidaleo M, Svetoni F, Volpe E, et al. Genotoxic stress inhibits ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9[J]. Oncotarget, 2015, 6(31):31740-31757.
|
| [10] |
Scharer CD, McCabe CD, Ali-Seyed M, et al. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells[J]. Cancer Res, 2009, 69(2):709-717.
|
| [11] |
Mi J, Ray P, Liu J, et al. In vivo selection against human colorectal cancer xenografts identifies an aptamer that targets RNA helicase protein DHX9[J]. Mol Ther Nucleic Acids, 2016, 5(4):e315.
|
| [12] |
Lee T, Paquet M, Larsson O, et al. Tumor cell survival dependence on the DHX9 DExH-box helicase[J]. Oncogene, 2016, 35(39):5093-5105.
|
| [13] |
Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1):W556-560.
|
| [14] |
Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform[J]. Neoplasia, 2004, 6(1):1-6.
|
| [15] |
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.
|
| [16] |
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5):401-404.
|
| [17] |
Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(D1):D956-963.
|
| [18] |
Liao Y, Wang J, Jaehnig EJ, et al. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs[J]. Nucleic Acids Res, 2019, 47(W1):W199-205.
|
| [19] |
Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017, 45(D1):D362-368.
|
| [20] |
Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma[J]. R Soc Open Sci, 2018, 5(12):181006.
|
| [21] |
Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma:an insight[J]. Cancer Cell Int, 2018(18):44.
|
| [22] |
Ding XX, Zhu QG, Zhang SM, et al. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy[J]. Oncotarget, 2017, 8(33):55715-55730.
|
| [23] |
Abdelhaleem M, Maltais L, Wain H. The human DDX and DHX gene families of putative RNA helicases[J]. Genomics, 2003, 81(6): 618-622.
|
| [24] |
Turanli B, Karagoz K, Bidkhori G, et al. Multi-omic data interpretation to repurpose subtype specific drug candidates for breast cancer[J]. Front Genet, 2019(10):420.
|
| [25] |
Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase[J]. Oncotarget, 2017, 8(19):30908-30921.
|
| [26] |
Lin YC, Yu YS, Lin HH, et al. Oxaliplatin-induced DHX9 phosphorylation promotes oncogenic circular RNA CCDC66 expression and development of chemoresistance[J]. Cancers, 2020, 12(3):697.
|
| [27] |
Cristini A, Groh M, Kristiansen MS, et al. RNA/DNA hybrid interactome identifies DXH9 as a molecular player in transcriptional termination and R-loop-associated DNA damage[J]. Cell Rep, 2018, 23(6):1891-1905.
|
| [28] |
Nogales V, Reinhold WC, Varma S, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs[J]. Oncotarget, 2016, 7(3):3084-3097.
|